logo-loader
viewZynerba Pharmaceuticals

Zynerba Pharmaceuticals wins US patent for treatment of Fragile X syndrome with its Zygel CBD gel

Zygel is currently being evaluated in CONNECT-FX, a double-blind placebo-controlled study of 204 pediatric Fragile X patients

Patented stamp
Fragile X syndrome is a rare genetic condition that causes developmental issues such as learning disabilities and cognitive impairment

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) received a US patent for its Zygel cannabidiol (CBD) cream used to treat Fragile X syndrome. 

The patent, which expires in 2038, covers the company's method of transdermally administering 250 milligrams to 500 milligrams of CBD daily in the form of a gel or cream.  

Zygel is currently being evaluated in CONNECT-FX, a double-blind placebo-controlled study of 204 pediatric Fragile X patients. The study is designed to measure the change in a Fragile X-specific behavioral checklist. 

READ: Zynerba logs dynamic 3Q, to report results from CONNECT-FX study with Zygel CBD gel in 2020

Patients who have completed the double-blind phase are currently enrolling in the 12-month open label phase, and topline data is expected in 2020.

Fragile X syndrome is a rare genetic condition that causes developmental issues such as learning disabilities and cognitive impairment.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Zynerba Pharmaceuticals

Price: 5.71 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $132.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read